AxoGen, Inc.
22.25+4.17 (+23.1%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · AXGN · USD
Key Stats
Market Cap
1.03BP/E (TTM)
-Basic EPS (TTM)
-0.05Dividend Yield
0%Recent Filings
8-K
FDA extends Avance BLA review
Axogen's BLA for Avance Nerve Graft hit a snag when the FDA deemed its recent manufacturing data submission a major amendment, pushing the PDUFA goal date to December 5, 2025. This three-month extension from the original timeline allows extra review time, with labeling feedback expected in November. The delay tests patience, yet underscores the agency's rigorous process. Forward-looking statements highlight risks like further FDA requests.
8-K
Axogen Q2 revenue surges 18%
Axogen reported Q2 2025 revenue of $56.7 million, up 18.3% from last year, with gross margin edging to 74.2%. Net income swung to $0.6 million from a $1.9 million loss, while adjusted EBITDA climbed to $9.3 million. Broad growth spanned all markets, boosted by expanded reimbursement covering 17 million new lives. The company raised full-year revenue guidance to at least $219 million, targeting 17% growth and net cash flow positivity. BLA approval for Avance Nerve Graft looms in September.
10-Q
Q2 FY2025 results
Axogen swung to an operating profit of $1.7M in Q2 FY2025 ended June 30, 2025, up from a $0.4M loss a year earlier, while revenues climbed 18.3% year-over-year to $56.7M on higher unit volume and better pricing. Gross margins edged up to 74.2% from 73.8%, thanks to fewer inventory write-offs, yet YTD margins dipped to 73.1% from 76.1% due to elevated product costs. Sales and marketing expenses rose 20.8% to support expansion in trauma centers, driving the topline but pressuring overall profitability; diluted EPS improved to $0.01 from -$0.04, consistent with 48.0M weighted shares. Cash and equivalents stood at $20.0M with $9.9M in investments, while $50.0M in debt matures in 2027-2028 at rates up to 13.0%; free cash flow not disclosed in the 10-Q. Revenue growth accelerated. Regulatory hurdles could delay BLA approval for Avance Nerve Graft.
8-K
Axogen annual meeting results
Axogen shareholders convened on June 18, 2025, electing eight directors including Paul Thomas and Amy Wendell to one-year terms, with votes split amid some withheld support. They ratified Deloitte & Touche as auditors, approved executive pay, and backed increasing the 2019 incentive plan's share reserve to 13,400,000. Shareholders favored annual say-on-pay votes. Governance continuity holds firm.
8-K
Axogen CFO transition announced
Axogen announced a CFO transition on May 8, 2025, with Nir Naor stepping down effective May 11 but advising through July 1 under a separation agreement that includes 75% base salary and continued equity vesting during the period. Lindsey Hartley, current VP of Finance with deep company knowledge, assumes the role May 12 with a $440,000 salary, 50% target bonus, and grants of 26,000 RSUs and PSUs. This internal promotion ensures continuity amid robust Q1 revenue growth of 17.4% to $48.6 million, yet Naor's exit risks short-term financial disruptions.
AMIX
Autonomix Medical, Inc.
1.05-0.04
AORT
Artivion, Inc.
44.99-0.27
APYX
Apyx Medical Corporation
2.95-0.15
AVNS
Avanos Medical, Inc.
11.43-0.15
INGN
Inogen, Inc
8.41-0.12
NRXS
Neuraxis, Inc.
3.02+0.00
ORGO
Organogenesis Holdings Inc.
4.17-0.02
RTGN
RETINALGENIX TECHNOLOGIES INC
3.75+0.00
TELA
TELA Bio, Inc.
1.32-0.12
XTNT
Xtant Medical Holdings, Inc.
0.90+0.03